VYOME HOLDINGS, INC.

NASDAQ: HIND (Vyome Holdings, Inc.)

Last update: 7 hours ago

10.96

1.97 (21.91%)

  • 1D 21.91%
  • 5D -30.10%
  • 1M -9.27%
  • 6M -91.94%
  • YTD -97.60%
  • 1Y -98.88%
  • 5Y -100.00%
Previous Close 8.99
Open 9.27
Volume 170,648
Avg. Volume (3M) 896,105
Market Cap 288,994,368
Price / Sales 782.12
52 Weeks Range
7.48 (-31%) — 1,213.00 (10967%)
Earnings Date 13 Nov 2025

AIStockmoo Score

-0.4
Analyst Consensus 0.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators -2.0
Average -0.38

Ownership

Name Date Shares Held
Cornerstone Planning Group Llc 30 Jun 2025 0
  • 3M
Date Type Details
21 Aug 2025 Announcement Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio
18 Aug 2025 Announcement Vyome Announces Strategic Review of Livechain (OTCID: LICH)
14 Aug 2025 Announcement Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
13 Aug 2025 Announcement Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
12 Aug 2025 Announcement Vyome Announces New Board of Directors with Deep MIT and AI Ties
07 Aug 2025 Announcement ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
24 Jul 2025 Announcement ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
22 Jul 2025 Announcement ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
21 Jul 2025 Announcement ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
01 Jul 2025 Announcement ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
27 Jun 2025 Announcement ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
26 Jun 2025 Announcement ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
25 Jun 2025 Announcement ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
12 Jun 2025 Announcement ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
09 Jun 2025 Announcement ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
03 Jun 2025 Announcement ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria